

match the sample sizes reported by the State.

*In Appendix D (List Sampling Frame Coverage Study), the following changes are being made with respect to the Annual Synar Report:*

**Question 2. Percent Coverage Found.** This question has been split into 4 sub-parts, asking the State to report the unweighted percent coverage found, the weighted percent coverage found, the number of outlets found through canvassing, and the number of outlets

matched on the list frame. The question has been split into these sub-parts to avoid SAMHSA/CSAP having to request additional clarifying information from the State during the review process.

**Question 3. Description of the Coverage Study Methods and Results.** This question has been expanded from one question to ten questions, which ask the State to provide specific information about the coverage study methods and results. Specifically, instead of one general question asking the State to

“provide a description of the coverage study methods and results,” the ten new questions query the State about specific aspects of the coverage study design, methodology and results. These specific questions will reduce the need for SAMHSA/CSAP to request additional clarifying information from the State during the review process.

There are no changes to Section II (Intended Use), or to Forms 1–5 or Appendix C.

#### ANNUAL REPORTING BURDEN

45 CFR citation	Number of respondents <sup>1</sup>	Responses per respondents	Hours per response	Total hour burden
Annual Report (Section 1—States and Territories) 96.130(e)(1–3) .....	59	1	15	885
State Plan (Section II—States and Territories) 96.130(e)(4,5)96.130(g) .....	59	1	3	177
<b>Total</b> .....	<b>59</b>	.....	.....	<b>1,062</b>

<sup>1</sup> Red Lake Indian Tribe is not subject to tobacco requirements.

Written comments and recommendations concerning the proposed information collection should be sent by April 12, 2010 to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202-395-5806.

Dated: March 5, 2010.

**Elaine Parry,**

*Director, Office of Program Services.*

[FR Doc. 2010-5400 Filed 3-11-10; 8:45 am]

**BILLING CODE 4162-20-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2009-N-0247]

#### Food and Drug Administration Transparency Task Force; Request for Comments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA) is soliciting comments from interested persons on ways in which FDA can increase transparency between FDA and regulated industry.

**DATES:** Submit electronic or written comments by April 12, 2010.

**ADDRESSES:** Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Afia Asamoah, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, rm. 2220, Silver Spring, MD 20993-0002, 301-796-4625, FAX: 301-847-3531, e-mail: [Afia.Asamoah@fda.hhs.gov](mailto:Afia.Asamoah@fda.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

Transparency promotes accountability and provides information to the public about government activities and initiatives. For FDA, providing information to the public in a timely, user-friendly manner is important to enhance the work of the agency.

Government transparency and accountability is a priority for the Obama Administration. On January 21, 2009, President Obama instructed executive departments and agencies to take appropriate action, consistent with law and policy, to disclose information to the public rapidly, and in a form that is easily accessible and user friendly. Executive departments and agencies have been charged with harnessing new technologies to make information about agency operations and decisions available online and readily available to the public. Executive departments and

agencies have been asked to solicit public input to identify information of greatest use to the public.

The Open Government Directive, issued by the Director of the Office of Management and Budget on December 8, 2009, further instructed executive departments and agencies to take specific actions to implement a transparent, collaborative, and participatory government.

FDA has formed an internal Transparency Task Force to develop recommendations for making useful and understandable information about FDA activities and decisionmaking more readily available to the public. The recommendations will focus on disclosing relevant information in a timely manner and in a user-friendly format, and in a manner compatible with the agency's goal of protecting confidential information, as appropriate. As a part of this transparency initiative, the Task Force has held two public meetings, on June 24, 2009, and November 3, 2009, and established a public docket to seek public input on these issues. As a result of the input the Task Force has received thus far, it has decided to separate the Transparency Initiative into three phases: (1) Creating a Web-based resource called “FDA Basics,” that provides information about commonly misunderstood agency activities and frequently asked questions; (2) improving FDA's disclosure of information to the public; and (3) improving FDA's transparency to regulated industry.

The first two phases are complete or well underway. “FDA Basics” was launched on FDA's Web site on January

12, 2010. The two public meetings held in 2009 and prior specific requests for comments focused on how FDA can improve its disclosure to the public. The Task Force soon plans to issue draft proposals related to those issues for public comment. This document focuses on the third phase of the transparency initiative.

## II. Scope of the Meeting

The Task Force is collecting information on how to improve FDA's transparency to regulated industry. It held three listening sessions with members of regulated industry on January 21, 27, and 28, 2010. FDA is making available transcripts and summaries of those listening sessions (see section IV of this document), and seeks public comment related to the issues raised in those sessions or other suggestions related to FDA's transparency to regulated industry. FDA is particularly interested in comments on how FDA can make improvements in the following areas:

1. Training and education for regulated industry about the FDA regulatory process in general and/or about specific new requirements.
2. The guidance development process.
3. Maintaining open channels of communication with industry routinely and during crises.
4. Providing useful and timely answers to industry questions about specific regulatory issues.
5. Communicating with sponsors during review of applications.

## III. Request for Comments

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) electronic or written electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. To permit time for interested persons to submit data, information, or views on this subject, submit comments by (see **DATES**). Where relevant, you should annotate and organize your comments to identify the specific question addressed by the question number referenced in the previous text. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management (see **ADDRESSES**) between 9 a.m. and 4 p.m., Monday through Friday.

## IV. Transcripts

Transcripts and summaries are accessible at <http://www.regulations.gov>

and on the Transparency Task Force Web site at <http://www.fda.gov/transparency>. Transcripts and summaries may be viewed at the Division of Dockets Management (see **ADDRESSES**). They will also be available in either hardcopy or on CD-ROM, after submission of a Freedom of Information request. Written requests are to be sent to Division of Freedom of Information (HFI-35), Office of Management Programs, Food and Drug Administration, 5600 Fishers Lane, rm. 6-30, Rockville, MD 20857.

Dated: March 5, 2010.

**Leslie Kux,**

*Acting Assistant Commissioner for Policy.*

[FR Doc. 2010-5377 Filed 3-11-10; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* National Cancer Institute Director's Consumer Liaison Group.

*Date:* March 24–26, 2010.

*Time:* March 24, 2010, 2 p.m. to 6 p.m.

*Agenda:* Welcome, Overview of the Cancer Genome Atlas, Expert Panel on the Cancer Genome Atlas.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Time:* March 25, 2010, 8:30 a.m. to 5:30 p.m.

*Agenda:* Report of the DCLG Genomics Working Group, Report on NCI Professional Judgment Budget, Board Discussion about Communicating with the Community about Genomics Research.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Time:* March 26, 2010, 8:30 a.m. to 1 p.m.

*Agenda:* Board Discussion about Engaging the Community around Genomics Research, Discussion with NCI Director.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Contact Person:* Benjamin Carollo, MPA, Advocacy Relations Manager, Office of

Advocacy Relations, Building 31, Room 10A30, 31 Center Drive, MSC 2580, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892-2580. 301-496-0307. [CAROLLO@MAIL.NIH.GOV](mailto:CAROLLO@MAIL.NIH.GOV).

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 26, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-5454 Filed 3-11-10; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center For Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Cancer Diagnostics and Therapeutics SBIR/STTR.

*Date:* March 18, 2010.

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Lambratu Rahman, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, 301-451-3493, [rahmanl@csr.nih.gov](mailto:rahmanl@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing